Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Min Zhou
Observed name:
MIN Zhou
Institution:
Guangzhou Medical University Cancer Hospital
Observed institutions:
Shanghai University of Medicine and Health Sciences,
Guangzhou Medical University Cancer Hospital,
Qilu Hospital of Shandong University,
Shandong First Medical University,
Guangzhou Medical University
ORCID:
0009-0008-9266-7780
Observed ORCID:
0009-0008-9266-7780
OpenAlex ID:
A5080045413
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial
2025
·
Yan Gao
, Yunhong Huang
, et al.
·
Cancer
·
19
PDF
Metal-polyphenol polymer modified polydopamine for chemo-photothermal therapy
2023
·
Li Xu
, Zhibing Luo
, et al.
·
Frontiers in Chemistry
·
13
PDF
A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study
2023
·
Yuqin Song
, Qingqing Cai
, et al.
·
Blood
·
9
Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
2025
·
Yuqin Song
, Qingqing Cai
, et al.
·
Blood
·
4
PDF
Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma
2024
·
Yuqin Song
, Qingqing Cai
, et al.
·
Blood
·
3
Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
2024
·
Yuqin Song
, Qingqing Cai
, et al.
·
Blood
·
3
PDF
PSF-lncRNA interaction as a target for novel targeted anticancer therapies
2024
·
Ren Liu
, Xiaojing Wang
, et al.
·
Biomedicine & Pharmacotherapy
·
3
Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study
2025
·
Yuqin Song
, Qingqing Cai
, et al.
·
Blood
·
2
PDF
Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
2023
·
Yuqin Song
, Qingqing Cai
, et al.
·
Blood
·
1
PDF
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study
2026
·
Ningjing Lin
, Qingqing Cai
, et al.
·
Advances in Therapy
Hemophagocytic lymphohistiocytosis in a neonate with neck skin abscess and thrombocytopenia
2024
·
Xiaoyang Huang
, Min Zhou
, et al.
·
Pediatrics & Neonatology
PDF
P1099: a Phase Ii, Multicenter, Single-arm Study of Parsaclisib, a Pi3kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China: Updated Results From the Study
2023
·
Zhong Zheng
, Huilai Zhang
, et al.
·
HemaSphere
Gemcitabine and celecoxib synergistically promote antitumor efficacy of αPD-1 by triggering immunogenic cell death
2023
·
Xiongjie Zhu
, Xia Yang
, et al.
·
Research Square
PDF
A phase II, multicenter, single-arm study of parsaclisib, a PI3Kδ inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study.
2022
·
Zhong Zheng
, Huilai Zhang
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
14
Citation count:
57
H-index:
4
I10-index:
2
Year
Topic
Type